Effectiveness of Cefoperazone-sulbactam alone and Combined with Tigecycline in the Treatment of Multi-drug Resistant Acinetobacter Baumannii Pulmonary Infection

Acinetobacter baumannii is non-fermentative and aerobic gram-negative bacteria, which belongs to acinetobacter group. 1 Because of the mild growth environment, acinetobacter baumannii is easy to multiply in large quantities, thus breaking the normal flora balance in the host body, leading to the immunity decline of the patients, and often causing infection.The most common organ affected by nosocomial infection caused by acinetobacter baumannii is lung.Drug resistance of this organism is becoming more and more serious, which leads to the limitation of clinical medication.Cefoperazone-sulbactam is the combined synergist of the third generation cephalosporin.Some studies have found that cefoperazone-sulbactam has bactericidal effect on acinetobacter. 2 Tigecycline is a new type of glycylcycline antibiotic, which is not subject to the changes of b-lactamase, target modification, efflux pump, and enzyme target.It can antagonize the ribosome drug resistance mechanism of acinetobacter baumannii and inhibit the bacteria to excrete the antibiotics.A study has shown that tigecycline is safe and effective in the treatment of multi-drug resistant bacteria in ICU. 3 An in vitro antimicrobial experiment showed that tigecycline combined with cefoperazonesulbactam has synergistic effect and is a good method for the treatment of multi-drug resistant acinetobacter baumannii. 4e aim of this study was to compare the effectiveness of cefoperazone-sulbactam alone or in combination with tigecycline in the treatment of multi-drug resistant acinetobacter baumannii pulmonary infection.